aTyr Pharma, Inc.

Based in the US, aTyr Pharma, Inc. specializes in developing innovative therapies derived from tRNA synthetase biology, focusing on addressing unmet medical needs in fibrosis and inflammation-related conditions. Founded in 2005 and headquartered in San Diego, California, aTyr Pharma, Inc. operates as a biotechnology firm that develops therapies for chronic inflammatory diseases.

The company has raised a total of USD 86. 30 mn through various funding rounds, with the most recent being a Private Placement/Follow on completed in May 2015. The leadership team includes CEO Jangwon Yoon and Sanjay Shukla, who have backgrounds in the biotechnology sector. The firm has executed a total of 11 deals throughout its history.

aTyr Pharma specializes in leveraging tRNA synthetase biology to develop innovative therapies aimed at treating fibrosis and inflammation-related conditions. The company's flagship product, Efzofitimod, is designed to target specific pathways involved in pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD). These therapies work by modulating immune responses and promoting tissue repair, addressing significant unmet medical needs in patients suffering from these debilitating diseases. aTyr Pharma serves a diverse client base that includes healthcare providers, research institutions, and pharmaceutical partners, primarily in North America and Europe.

The company's offerings are positioned to enhance patient outcomes in chronic inflammatory diseases through advanced therapeutic interventions. aTyr Pharma's revenue generation for the year 2024 is reported at USD 235,000, with an EBITDA of USD -67,206,000. The firm's revenue model is primarily driven by partnerships and collaborations with other biotechnology and pharmaceutical companies, as well as through clinical trial sponsorships. Structured agreements may involve milestone payments tied to the development of Efzofitimod and other investigational candidates, facilitating access to aTyr's proprietary therapies for partners who incorporate them into their treatment regimens.

aTyr Pharma aims to further enhance its portfolio with the development and launch of new products tailored for chronic inflammatory conditions. The most recent funding will support these initiatives, allowing the company to expand its reach into new geographic markets, particularly in Europe and Asia, with plans set to initiate by 2025. The successful IPO completed in May 2015 raised USD 75 mn, providing a foundation for ongoing research and development efforts.